428 results about "Improved solubility" patented technology

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

An edible pet chew is disclosed that is comprised of fibrous protein, water absorbing polymer, plasticizer and water. The pet chew provides excellent textural properties and improved solubility in the stomach and intestinal environment for improved pet safety.

This invention provides a soluble inclusion complex formed of a water-insoluble lipophilic compound and an amphiphilic polymer and which demonstrated improved solubility and stability. The lipophilic compound within the inclusion complex may consist of pharmaceutical compounds, food additives, cosmetics, agricultural products and veterinary products. The invention also provides novel methods for preparing the inclusion complex, as well as a novel chemical reactor for forming the inclusion complex.

The present invention provides an intraoral quickly disintegrating tablet containing a phosphodiesterase inhibitor having an effect of improving the erectile dysfunction and a method for manufacturing the tablet. The present invention also provides an intraoral quickly disintegrating tablet containing a slightly soluble pharmaceutical agent having an improved solubility and a method for manufacturing the tablet. That is, it is an intraoral quickly disintegrating tablet containing a cyclic GMP phosphodiesterase inhibitor and a saccharide, and a method for manufacturing the tablet. Further, it is a method for manufacturing an intraoral quickly disintegrating tablet, which comprises dissolving a slightly soluble pharmaceutical agent in an organic solvent or an aqueous organic solvent together with a surfactant and/or a water-soluble polymer, coating the solution on a filler or granulating it with a filler to obtain molded products, mixing a saccharide with them, adding an organic solvent, water or an aqueous organic solvent thereto, followed by kneading, and subjecting it to a compression-molding.

The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby, the paclitaxel solid dispersion being highly homogeneous and showing an improved solubility, thereby being effectively used for the preparation of paclitaxel injection and oral preparation having a high bioavailability.

The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their improved deposition of dispersed phase materials onto keratin substrates, textile substrates, and hard-surface substrates, their improved lather performance, and their improved rheology in applications such as personal care and household care products and textile applications.

Soluble fibrous structures and more particularly soluble fibrous structures that contain one or more fibrous elements, such as filaments, having one or more fibrous element-forming materials and one or more active agents present within the fibrous elements, wherein the fibrous structure exhibits improved dissolution properties compared to known soluble fibrous structures, and method for making such improved fibrous structures are provided.

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and/or cosolvent and/or antioxidant or preservative.

The invention relates to water soluble or water dispersible powders, tablets, or precursors therefor based on a carbohydrate matrix with improved dissolution properties in water. These components are subjected to treatment with a gas so that gas is entrapped therein, and sufficient closed porosity is provided so that gas entrapped therein promotes dissolution or dispersion upon contact with water. The powders or tablets may be pharmaceuticals or foods that optionally contain an active ingredient therein.

PCT No. PCT/US97/12894 Sec. 371 Date Feb. 1, 1999 Sec. 102(e) Date Feb. 1, 1999 PCT Filed Jul. 23, 1997 PCT Pub. No. WO98/04662 PCT Pub. Date Feb. 5, 1998Disclosed are detergent compositions with improved solubility having a bulk density of at least 600 g/l, comprising a branched surfactant and from about 1% to about 3% a particulate acid source which is citric acid and an alkaline source, wherein said acid source and alkaline source are capable of reacting together to produce a gas, and wherein about 80% or more of the acid source has a particle size in the range of from about 150 microns to about 710 microns, with at least 37% by weight of the acid source having a particle size of about 350 microns or less.

The present invention relates to quinone prodrug compositions and therapeutic methods using such prodrug compositions. Preferably, the quinone compounds of the invention are napthoquinone compounds such as β-lapachone or β-lapachone analogs. The quinone prodrug compositions of the invention exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved plasma half-life in vivo.

The invention herein provides for an oral pharmaceutical composition adapted for use in capsular dosage forms comprising acetaminophen and a lactate salt alone or in combination with an acetate salt. Compositions of the invention exhibit improved solubility characteristics of the active ingredient per given fill volume, thereby permitting the use of smaller capsule sizes to deliver a given effective dose of the active ingredient. Compositions of the invention also exhibit improved clarity per concentration of active ingredient. The invention also provides for a capsular dosage form containing the composition.

The present invention provides isoflavone compositions exhibiting improved solubility (e.g., light transmittance), taste, color, and texture characteristics, and methods for making the same. The isoflavone compositions are useful for incorporation in a variety of foodstuffs, beverages, dietary supplements, and pharmaceutical compositions allowing for improved taste, texture, color, and optical properties of the same.

Improved, solid water-soluble fertilizer (WSF) compositions are presented which comprise at least one acid (optionally nutritive) and at least one basic fertilizer component. In one or more embodiments of the present invention, the WSF compositions demonstrate improved solubility of one or more nutrients or additives in solution, do not require additional dissolution aids or anti-caking agents, demonstrate fast dissolution times, produce precipitate free solutions, are readily compounded without intermediate wetting or drying steps, do not generate gas, and demonstrate improved stability under typical usage conditions. Finally, the WSF compositions may be used in improved processes for the creation of stock solutions, optionally with cold water, and/or delivery of nutrients to plants.

A detergent tablet for use in a washing machine, the tablet having one or more phases at least one of which is in the form of a compressed particulate solid comprising a) a polymeric disintegrant having a particle size distribution such that at least 90% by weight thereof has a particle size below about 0.3 mm and at least 30% by weight thereof has a particle size below about 0.2 mm; and b) a water-soluble hydrated salt having a melting point in the range from about 30° C. to about 95° C. The detergent tablets display improved dissolution, strength and long-term storage characteristics.

This invention is a novel pharmaceutical composition of ezetimibe or a pharmaceutically acceptable salt thereof comprising one or more pharmaceutically acceptable excipients having high bioavailability with improved solubility and dissolution rate which is stable throughout the shelflife, methods for their preparation, and methods for treatment using the same.

A novel system for non-parenteral formulations comprising cyclodextrins is disclosed. The system includes hydrophobic cyclodextrins and amino acids and homo- or co-polymers thereof. The cyclodextrins and amino acids form a complex with pharmaceutical and other ingredients to achieve greatly improved solubility and/or enhance stability. The complexes can be used for delivery to mammals in a wide variety of non-parenteral formulations.

Disclosed is a water repellent additive for an immersion resist, which is composed of a fluorine-containing polymer that has a repeating unit represented by general formula (1). By adding the water repellent additive to a resist composition, the resist composition can be controlled to have high water repellency during exposure and to exhibit improved solubility in a developing solution during development.

[In the formula, R¹ represents a hydrogen atom, a fluorine atom, a methyl group or a trifluoromethyl group; R² represents a heat-labile protecting group; R³ represents a fluorine atom or a fluorine-containing alkyl group; and W represents a divalent linking group.]

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Water-soluble anhydrous film containing (i) at least one water-soluble or water-dispersible film-forming polymer, (ii) at least one polysaccharide thickening agent, (iii) at least one water-soluble or water-dispersible oxyalkylenated polysiloxane and (iv) one or more plasticizers chosen from polyols. The invention also relates to the product obtained by mixing at least one film with an aqueous composition and to a kit for the formulation of a cosmetic product.

An organic solar cell material and the preparation thereof belong to the field of organic photoelectric materials. The invention discloses an organic solar cell material which contains C60-triphenylamine-thiofuran ternary system which is a fullerene-contained D-A (Donor-Accepter) type difunctional material, wherein the triphenylamine and the thiofuran are in stellated structure. Compared with the fullerene, the compound has greatly improved solubility in organic solvent, so that the process for manufacturing the large-area solar cell is simplified, stronger absorption is ensured in a visible region with a maximum of about 500 nm that is similar to the maximum of solar radiation energy of 475 nm, matching of the compound and solar spectrum radiation is enhanced, solar spectrum response of the material, as well as the photoelectric conversion efficiency is improved. In the invention, the compound can be polymerized on a macromolecule through simple ligand modification, and is made into PLED by spin coating, so as to overcome the defects of possible decomposition by heating and poor crystallization-resistant performance of the small-molecule luminescent material in the evaporation process.

The present invention relates to a lyophilized pharmaceutical composition for injection having superior storage stability comprising a taxoid, and a method thereof. More specifically, the present invention relates to a lyophilized pharmaceutical composition for injection having improved solubility and stability of dilution compared to the conventional preparations by dissolving a water-insoluble taxoid in distilled water added with a hydrophilic polymer such as hydroxypropylmethyl cellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) cyclodextrin (CD), and lyophilizing the mixture and a method thereof.

Disclosed is a method for providing amino acids in a form having improved solubility and/or improved suspension properties, and a product made by the method. The method also provides protein and amino acid compositions having decreased viscosity following heat treatment.